Brind.

Iovance Biotherapeutics received conditional approval from Health Canada for its drug Amtagvi.

3 reports, 3 independent Updated Jun 5

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Iovance Biotherapeutics received conditional approval from Health Canada for its drug Amtagvi.

Who's involved

What this event is mainly about

Health Canada Iovance Biotherapeutics

Keep exploring

The entities involved

Health Canada
Department of the Canadian Government that oversees public health
- Canadian Blood Services faces union calls for contract termination after Health Canada issued a non-compliance rating.Fri 17:53
- Health Canada approved the new indication for IMCIVREE, a product focused on the North American market, while Jennifer Lee serves as EVP for Rhythm.Fri 15:22
Iovance Biotherapeutics
American biopharmaceutical startup

Nothing else this week.

Related events

Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.Jun 20

Coverage

Newest first; wire copies grouped

Jun 5yahoo.com
Aug 23Insider MonkeyIovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Most Oversold Penny Stocks to Buy Now. On August 18, Iovance
Aug 19GlobeNewswireIovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma